These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31398372)

  • 1. Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment.
    Luo D; Liu Y; Chen R; Niu M; Liu L; Li X; Li Q; Huang B; Wang J; Xu D; Lin S
    Antiviral Res; 2019 Oct; 170():104579. PubMed ID: 31398372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
    Shirvani-Dastgerdi E; Winer BY; Celià-Terrassa T; Kang Y; Tabernero D; Yagmur E; Rodríguez-Frías F; Gregori J; Luedde T; Trautwein C; Ploss A; Tacke F
    J Hepatol; 2017 Aug; 67(2):246-254. PubMed ID: 28392234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.
    Liu Y; Chen R; Liu W; Si L; Li L; Li X; Yao Z; Liao H; Wang J; Li Y; Zhao J; Xu D
    Antiviral Res; 2021 May; 189():105058. PubMed ID: 33711338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.
    Chen R; Liu Y; Luo D; Si L; Huang B; Wang J; Li X; Cheng F; Xu D; Duan C
    Antiviral Res; 2020 Aug; 180():104852. PubMed ID: 32569703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
    Cassino L; Benetti S; Fay F; Tanno H; Quarleri J
    BMC Infect Dis; 2011 Jun; 11():178. PubMed ID: 21696601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
    Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
    J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
    Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
    Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
    Li X; Liu Y; Xin S; Ji D; You S; Hu J; Zhao J; Wu J; Liao H; Zhang XX; Xu D
    Microb Drug Resist; 2017 Jun; 23(4):516-522. PubMed ID: 27792585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
    Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
    Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
    Sayan M; Buğdacı MS
    Mikrobiyol Bul; 2013 Jul; 47(3):544-9. PubMed ID: 23971933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
    Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
    J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice.
    Liu Y; Zhou Y; Li X; Niu M; Chen R; Shao J; Si L; Luo D; Lin Y; Li L; Zhang K; Xiao X; Xu Z; Liu M; Lu M; Zoulim F; Xu D
    Emerg Microbes Infect; 2019; 8(1):354-365. PubMed ID: 30866789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
    Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
    J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: an Indian subcontinent perspective.
    Ismail AM; Sharma OP; Kumar MS; Eapen CE; Kannangai R; Abraham P
    Antiviral Res; 2013 May; 98(2):209-16. PubMed ID: 23485939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
    Park ES; Lee AR; Kim DH; Lee JH; Yoo JJ; Ahn SH; Sim H; Park S; Kang HS; Won J; Ha YN; Shin GC; Kwon SY; Park YK; Choi BS; Lee YB; Jeong N; An Y; Ju YS; Yu SJ; Chae HB; Yu KS; Kim YJ; Yoon JH; Zoulim F; Kim KH
    J Hepatol; 2019 Jun; 70(6):1093-1102. PubMed ID: 30794889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
    Choe WH; Kim K; Lee SY; Choi YM; Kwon SY; Kim JH; Kim BJ
    World J Gastroenterol; 2019 Sep; 25(33):4985-4998. PubMed ID: 31543688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.